Renal Ablation; a phase 1 study evaluating the integration of Hypofractional renal ablative radiation therapy in the setting of metastatic renal cell carcinoma
To evaluate the safety/toxicity profile of renal radio-ablation in the setting of metastatic renal cell carcinoma. The assessment of renal function post radio-ablation, primary and metastatic tumour response to renal radio-ablation, incidence of bleeding post treatment compared to historical data and documentation and characterization of toxicities associated with renal radio-ablation. There will also be an assessment of quality of life for the patients, and correlative renal function imaging pre and post radiation therapy.
See Trial Summary.
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society